Human umbilical cord mesenchymal stem cell-derived exosomes ameliorate renal fibrosis in diabetic nephropathy by targeting Hedgehog/SMO signaling

• Published in: The FASEB journal Vol. 38; no. 7; p. e23599
• Main Authors: Zhang, Ke, Zheng, Shuo, Wu, Jiasheng, He, Jing, Ouyang, Yu, Ao, Chunchun, Lang, Ruibo, Jiang, Yijia, Yang, Yifan, Xiao, Huan, Li, Yu, Li, Mao, Wang, Huiming, Li, Changyong, Wu, Dongcheng
• Format: Journal Article
• Language: English
• Published: United States 15.04.2024
• Subjects: Hedgehog signaling; epithelial‐mesenchymal transition; human umbilical cord mesenchymal stem cells; exosomes; diabetic nephropathy; kidney fibrosis
• ISSN: 1530-6860
• DOI: 10.1096/fj.202302324R

Diabetic nephropathy (DN) is the leading cause of end-stage renal disease globally. Currently, there are no effective drugs for the treatment of DN. Although several studies have reported the therapeutic potential of mesenchymal stem cells, the underlying mechanisms remain largely unknown. Here, we report that both human umbilical cord MSCs (UC-MSCs) and UC-MSC-derived exosomes (UC-MSC-exo) attenuate kidney damage, and inhibit epithelial-mesenchymal transition (EMT) and renal fibrosis in streptozotocin-induced DN rats. Strikingly, the Hedgehog receptor, smoothened (SMO), was significantly upregulated in the kidney tissues of DN patients and rats, and positively correlated with EMT and renal fibrosis. UC-MSC and UC-MSC-exo treatment resulted in decrease of SMO expression. In vitro co-culture experiments revealed that UC-MSC-exo reduced EMT of tubular epithelial cells through inhibiting Hedgehog/SMO pathway. Collectively, UC-MSCs inhibit EMT and renal fibrosis by delivering exosomes and targeting Hedgehog/SMO signaling, suggesting that UC-MSCs and their exosomes are novel anti-fibrotic therapeutics for treating DN.